Bringing the fundamentals into focus…
Back to Eli Lilly and Company
How Eli Lilly and Company stacks up
LLY · against 1,339 other Healthcare companies
Valuation
50/ 100
Below the middle of the pack.
Ranked #664 of 1,340 · scores higher than 50% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 50–59, including LLY · Click a bar to see the companies
Why valuation scores 50?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 3.1% vs peer median 3.9%
- Earnings yield is close to the peer norm. Earnings yield: 2.4% vs peer median 1.4%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.3% vs peer median 0.0%
Metric by metric
Position: dot = LLY, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LLY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 2.5% | 1.4% | 57% | 30% | |
| EBITDA yieldHigher is better · 1,359 reported | 3.8% | 4.1% | 48% | 50% | |
| Free cash flow yieldHigher is better · 700 reported | 1.3% | -1.1% | 59% | 20% | |
| Book yieldHigher is better · 1,237 reported | 3.2% | 34.8% | 8% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around LLY| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.2B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.2B HKD (≈$151M) | 99 | 72 | |
| 1 | 14.6B HKD (≈$1.9B) | 99 | 64 | |
| 1 | 46.3B HKD (≈$5.9B) | 99 | 56 | |
| 1 | 4.8B HKD (≈$612M) | 99 | 51 | |
| 664 | 49.4B USD | 50 | 60 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score